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Background
Bioactive peptides prospection is important for biotech-
nology field as well as a starting point in many research
areas, such as: new drugs development and production
of genetically modified plants [1]. In general, bioactive
peptides have been identified as candidates for the new
drugs development because their intrinsic properties
concerning some potential activities, like high specificity,
potency, less toxicity, and also chemistry and biological
diversity [2]. Peptides can present diverse activities such
as antimicrobial, opioids, hypotensive, antithrombotic
among others. In 2010, around 60 synthetic peptides
with therapeutic potential have been available to phar-
maceutical marketing and can be used in many patholo-
gies like, allergies, asthma, arthritis, cardiovascular
diseases, diabetes, gastrointestinal dysfunction, growth
problems, inflammation, obesity, infectious diseases,
cancer, osteoporosis, pain, vaccines and others. [3,4].
For pharmaceutical industry, in therapeutic area, the
most promising projects are those that focus on cancer,
pain, diabetes, Alzheimer’s disease and depression [5].
This study aims to design sequences of synthetic pep-
tides that may have dual activity: antinociceptive and
hypotensive. These peptides act on different targets,
opioids receptors and angiotensin converting enzyme
(ACE), respectively.
Methods
Peptides primary structure prediction was based on pre-
vious work of our group, which focused on prospection
and bioactive peptides characterization. These studies
were based on the knowledge available on the literature
about the biological properties of specific protein domains,
molecular targets and drug actions. The peptides were
synthesized by solid-phase chemical synthesis using Fmoc
strategy followed by purification on high performance
liquid chromatography. Purity and confirmation of the
primary structure were determined by mass spectrometry,
MALDI and ESI. The peptides were tested in mice
(6-8 per group) intraperitoneally, equimolar to morphine
(positive control) in order to assess its possible antinoci-
ceptive activity through hot plate and tail flick assays.
Results and conclusions
It was possible to evaluate the antinociceptive activity of
these two designed peptides, which present unpublished
sequences. Both exhibited pharmacological activity in vivo,
which may be denominated opioid receptor agonists,
because they promoted antinociception in mice when
exposed to thermal stimulation. In naloxone presence,
there was no activity, so it can be concluded that the pep-
tides interact with opioid receptors. In vivo tests showed
that synthetic peptides have delayed response, longer
activity compared to morphine and may have cross the
blood-brain barrier. Thus, it is interesting continue study-
ing therapeutic potential of these peptides to contribute
with development for new drug candidates.
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